How do I install the Icsm Prostate Monitoring Tt skill?

Run npx skillmds@latest add dromlakhani/icsm-prostate-monitoring-tt in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Icsm Prostate Monitoring Tt safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Icsm Prostate Monitoring Tt?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Icsm Prostate Monitoring Tt free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Icsm Prostate Monitoring Tt?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Icsm Prostate Monitoring Tt by dromlakhani

Name: Icsm Prostate Monitoring Tt
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Icsm Prostate Monitoring Tt

Recommends prostate-specific antigen (PSA) testing and digital rectal examination (DRE) to monitor prostate health during testosterone therapy, following evidence-based guidelines for prostate cancer surveillance. Use when managing a patient on testosterone and questioning whether prostate checks are needed or when PSA/DRE are due.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Monitor prostate health with PSA and DRE during testosterone therapy

STEP 1 — Gather Information

Collect patient demographics, testosterone therapy formulation and start date, baseline PSA and DRE results (if available), urinary/sexual symptoms, and risk factors (family history of prostate cancer, prior elevated PSA, abnormal DRE, or comorbidities affecting prostate health).

STEP 2 — Rule In / Rule Out

Determine if the patient is currently on testosterone therapy with no known active prostate cancer and no unresolved elevated PSA or abnormal DRE requiring urologic evaluation; if yes, proceed to timing assessment, if no, defer PSA/DRE and address the contraindication first.

STEP 3 — Classify or Stratify

Assess time since last PSA and DRE: classify as due for PSA if ≥3 months since last PSA (baseline, 3‑month, 6‑month, or yearly interval) and due for DRE if ≥3 months since last DRE (baseline, 3‑month, or 6‑month interval) per the ICSM monitoring schedule.

STEP 4 — Decide

Order PSA and DRE if due; if PSA >4 ng/mL (or age‑specific threshold) or DRE shows nodularity, induration, or asymmetry, refer to urology for further evaluation; otherwise continue testosterone therapy and repeat testing per schedule.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on PSA/DRE to exclude prostate cancer; evaluate symptomatic patients regardless of PSA. Do not initiate testosterone in men with untreated or active prostate cancer. Do not ignore PSA velocity >0.75 ng/mL/year or abrupt changes. Avoid DRE in patients with acute anal pathology, severe thrombocytopenia, or recent prostate biopsy. Do not substitute PSA alone for combined PSA + DRE assessment.

Concrete Clinical Example

A 58‑year‑old man begins testosterone gel for hypogonadism. Baseline PSA 0.8 ng/mL, DRE normal. At 3 months PSA 0.9 ng/mL, DRE normal. At 6 months PSA 1.0 ng/mL, DRE normal. At 12 months PSA 1.2 ng/mL (DRE not required per guideline); therapy continues with annual PSA monitoring.

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036

---name: icsm-prostate-monitoring-ttdescription: Recommends prostate-specific antigen (PSA) testing and digital rectal examination (DRE) to monitor prostate health during testosterone therapy, following evidence-based guidelines for prostate cancer surveillance. Use when managing a patient on testosterone and questioning whether prostate checks are needed or when PSA/DRE are due.---# Monitor prostate health with PSA and DRE during testosterone therapy## STEP 1 — Gather InformationCollect patient demographics, testosterone therapy formulation and start date, baseline PSA and DRE results (if available), urinary/sexual symptoms, and risk factors (family history of prostate cancer, prior elevated PSA, abnormal DRE, or comorbidities affecting prostate health).## STEP 2 — Rule In / Rule OutDetermine if the patient is currently on testosterone therapy with no known active prostate cancer and no unresolved elevated PSA or abnormal DRE requiring urologic evaluation; if yes, proceed to timing assessment, if no, defer PSA/DRE and address the contraindication first.## STEP 3 — Classify or StratifyAssess time since last PSA and DRE: classify as due for PSA if ≥3 months since last PSA (baseline, 3‑month, 6‑month, or yearly interval) and due for DRE if ≥3 months since last DRE (baseline, 3‑month, or 6‑month interval) per the ICSM monitoring schedule.## STEP 4 — DecideOrder PSA and DRE if due; if PSA >4 ng/mL (or age‑specific threshold) or DRE shows nodularity, induration, or asymmetry, refer to urology for further evaluation; otherwise continue testosterone therapy and repeat testing per schedule.## Clinical Guardrails / Mimics / PitfallsDo not rely solely on PSA/DRE to exclude prostate cancer; evaluate symptomatic patients regardless of PSA. Do not initiate testosterone in men with untreated or active prostate cancer. Do not ignore PSA velocity >0.75 ng/mL/year or abrupt changes. Avoid DRE in patients with acute anal pathology, severe thrombocytopenia, or recent prostate biopsy. Do not substitute PSA alone for combined PSA + DRE assessment.## Concrete Clinical ExampleA 58‑year‑old man begins testosterone gel for hypogonadism. Baseline PSA 0.8 ng/mL, DRE normal. At 3 months PSA 0.9 ng/mL, DRE normal. At 6 months PSA 1.0 ng/mL, DRE normal. At 12 months PSA 1.2 ng/mL (DRE not required per guideline); therapy continues with annual PSA monitoring.**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036

Frequently asked questions